The Comparative Study of Dipeptidyl Peptidase-IV Inhibitor [sitagliptin] and Sulfonylurea [glimepiride] on the Effect of Improving Glucose Variability and Oxidative Stress in Type 2 Diabetic Patients With Inadequate Glycemic Control on Metformin.

Trial Profile

The Comparative Study of Dipeptidyl Peptidase-IV Inhibitor [sitagliptin] and Sulfonylurea [glimepiride] on the Effect of Improving Glucose Variability and Oxidative Stress in Type 2 Diabetic Patients With Inadequate Glycemic Control on Metformin.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Sitagliptin (Primary) ; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Jul 2013 Status changed from recruiting to completed, based on results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
    • 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top